Article

OASIS to J&J: Acuvue Oasys is infringement

Glendora, CA?OASIS Medical filed a lawsuit against Johnson & Johnson/Johnson & Johnson Vision Care Inc. (J&J) in the U.S. District Court in the Central District of California, alleging that the companies' use of the name OASYS infringes and dilutes OASIS Medical's trademark rights. Acuvue Oasys with Hydraclear Plus is a trademark of Johnson & Johnson Vision Care Inc. for its line of Acuvue contact lenses.

Glendora, CA-OASIS Medical filed a lawsuit against Johnson & Johnson/Johnson & Johnson Vision Care Inc. (J&J) in the U.S. District Court in the Central District of California, alleging that the companies' use of the name OASYS infringes and dilutes OASIS Medical's trademark rights. Acuvue Oasys with Hydraclear Plus is a trademark of Johnson & Johnson Vision Care Inc. for its line of Acuvue contact lenses.

"Our company spent 18 years developing a reputation for itself under the name 'OASIS,' " said Norman Delgado, president of OASIS Medical. "J&J has adopted the same name for its new contact lenses, which, like OASIS' products, are designed for patients suffering from dry eye. Considering the impact this will have on our company, we believe that we must defend our trademarks and the use of them."

Introduced in August 2005, Acuvue Oasys with Hydraclear Plus is the first daily wear contact lens made from senofilcon A, a new silicone hydrogel material said to be 50% smoother than other silicone hydrogel lenses, according to the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.